| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8215871 | International Journal of Radiation Oncology*Biology*Physics | 2015 | 9 Pages |
Abstract
Although there is deterioration in HRQL following CRT, this resolves within 3Â weeks. HRQL data support the use of capecitabine- over gemcitabine-based chemoradiation. The QLQ-PAN26 is a reliable and valid tool for use in patients receiving CRT.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Christopher N. MSc, Somnath FRCP, John MD, Stephen MD, Tom FRCR, Alec MD, George MBBS, John MD, Ross A. MD, Jane M. MD, Sarah BSc, Peter MSc, Gareth PhD, Tim FRCR, Colin MChir, FRCS,